• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » John Fox

John Fox

Articles

ARTICLES

Biome study finds regional limitations to disease models

Sep. 5, 2018
By John Fox
The findings of a Chinese-led international study into regional variations in reference ranges and models of diseases clearly related to dysbiosis in the gut microbiome could have important public health implications for managing disorders including fatty liver and other metabolic diseases.
Read More

New lymph node discovery may improve vaccines

Sep. 5, 2018
By John Fox
Australian researchers have identified for the first time in decades a previously unknown immune system microstructure, which they have demonstrated to be responsible for immunological memory. This is a key finding, as it may be used to rapidly mobilize secondary antibody responses and improve vaccine efficacy, the researchers wrote in a study published In the Aug. 22, 2018, edition of Nature Communications.
Read More

Biome study finds regional limitations to disease models

Sep. 5, 2018
By John Fox
The findings of a Chinese-led international study into regional variations in reference ranges and models of diseases clearly related to dysbiosis in the gut microbiome could have important public health implications for managing disorders including fatty liver and other metabolic diseases.
Read More

New lymph node discovery may improve vaccines

Aug. 30, 2018
By John Fox

New lymph node discovery may improve vaccines

Aug. 30, 2018
By John Fox
Australian researchers have identified for the first time in decades a previously unknown immune system microstructure, which they have demonstrated to be responsible for immunological memory.
Read More

ALS modeling identifies dopamine agonist as potential therapy

Aug. 29, 2018
By John Fox
A novel means of modeling sporadic amyotrophic lateral sclerosis (SALS) using motor neurons derived from induced pluripotent stem (iPS) cells should provide new insights into the pathology of the disease, researchers reported in the Aug. 20, 2018, edition of Nature Medicine.
Read More

ALS modeling identifies dopamine agonist as potential therapy

Aug. 28, 2018
By John Fox

ALS modeling identifies dopamine agonist as potential therapy

Aug. 27, 2018
By John Fox
A novel means of modeling sporadic amyotrophic lateral sclerosis (SALS) using motor neurons derived from induced pluripotent stem (iPS) cells should provide new insights into the pathology of the disease, researchers reported in the Aug. 20, 2018, edition of Nature Medicine.
Read More

Mutation burden predicts benefit of PD-1-treated NSCLC

Aug. 22, 2018
By John Fox
An elevated tumor mutational burden (TMB) in the blood has now demonstrated its potential as a reliable clinical biomarker for predicting the clinical efficacy of the checkpoint inhibitor Tecentriq (atezolizumab, Roche Holding AG) in treating patients with advanced non-small-cell lung cancer (NSCLC), a Sino-U.S. study has shown.
Read More

Mutation burden predicts benefit of PD-1-treated NSCLC

Aug. 16, 2018
By John Fox
View All Articles by John Fox

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 25, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 25, 2025.
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • Pfizer describes new STAT6 inhibitors

    BioWorld Science
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe